Low-dose Dexmedetomidine and Postoperative Delirium After Cardiac Surgery

NAActive, not recruitingINTERVENTIONAL
Enrollment

502

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

July 3, 2021

Study Completion Date

August 31, 2025

Conditions
Cardiac SurgeryCardiopulmonary BypassDexmedetomidineDeliriumSurvival
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.

DRUG

Placebo

Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.

Trial Locations (2)

100034

Beijing University First Hospital, Beijing

100037

Fuwai Hospital of Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Fu Wai Hospital, Beijing, China

OTHER

lead

Dong-Xin Wang

OTHER

NCT03624595 - Low-dose Dexmedetomidine and Postoperative Delirium After Cardiac Surgery | Biotech Hunter | Biotech Hunter